Trials / Unknown
UnknownNCT05240404
Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
A Randomized Phase II Study of Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 116 (estimated)
- Sponsor
- Xiangya Hospital of Central South University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This phase II study is to evaluate the efficacy of the adjuvant immunotherapy after curative-intent ablation for recurrent hepatocarcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toripalimab | toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months |
| PROCEDURE | Thermal ablation | The ablation operation was performed under local or compound anesthesia and guided by ultrasonography (US) or computed tomography (CT). To ensure complete destruction of the tumor, the ablation area must exceed the tumor boundary 1.0 cm. |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2023-07-31
- Completion
- 2024-07-31
- First posted
- 2022-02-15
- Last updated
- 2022-02-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05240404. Inclusion in this directory is not an endorsement.